Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy
المؤلفون المشاركون
Bernatsky, Sasha
Moura, Cristiano S.
Rosenberg, Zale B.
Abrahamowicz, Michal
Behlouli, Hassan
Pilote, Louise
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-03-11
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Objective.
To compare dipeptidyl peptidase-4 (DPP-4) inhibitors with neutral protamine Hagedorn (NPH) insulin, in terms of effectiveness and safety for the management of patients with type 2 diabetes mellitus (DM2) not controlled on metformin and sulfonylureas.
Methods.
A retrospective cohort study of individuals with DM2 newly dispensed with either DPP-4 inhibitors or NPH as third-line therapy, after metformin and sulfonylurea.
Treatment discontinuation, macrovascular outcomes, and hypoglycemia were compared using multivariable Cox regression models, adjusted for sex, age, year of cohort entry, place of residence, hypertension, past history of hypoglycemia, diabetic ketoacidosis, comorbidities, and number of visits to emergency departments, outpatient physician, and hospitalizations.
Results.
Treatment discontinuation and hypoglycemia occurred more frequently with NPH than with DPP-4 inhibitor users.
In the adjusted Cox model, the use of NPH compared to that of DPP-4 inhibitors was associated with a higher risk of discontinuation (HR: 1.33; 95% CI 1.27–1.40) and hypoglycemia (HR: 2.98; 95% CI 2.72–3.28).
Risk of cardiovascular events was similar across groups.
Conclusions.
This real-world analysis suggests that DM2 patients initiating third-line therapy with NPH have poorer control of diabetes when compared to DPP-4 inhibitor initiators.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Moura, Cristiano S.& Rosenberg, Zale B.& Abrahamowicz, Michal& Bernatsky, Sasha& Behlouli, Hassan& Pilote, Louise. 2018. Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy. Journal of Diabetes Research،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1183615
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Moura, Cristiano S.…[et al.]. Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy. Journal of Diabetes Research No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1183615
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Moura, Cristiano S.& Rosenberg, Zale B.& Abrahamowicz, Michal& Bernatsky, Sasha& Behlouli, Hassan& Pilote, Louise. Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy. Journal of Diabetes Research. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1183615
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1183615
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر